SABS
NASDAQ · Biotechnology
Sab Biotherapeutics Inc
$3.90
+0.05 (+1.30%)
Open$3.86
Previous Close$3.85
Day High$3.95
Day Low$3.85
52W High$5.15
52W Low$1.85
Volume—
Avg Volume432.6K
Market Cap341.20M
P/E Ratio25.70
EPS$-1.42
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+705.4% upside
Current
$3.90
$3.90
Target
$31.41
$31.41
$26.29
$31.41 avg
$48.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 92.27M | 83.15M | 89.97M |
| Net Income | 5.58M | 4.38M | 5.69M |
| Profit Margin | 6.1% | 5.3% | 6.3% |
| EBITDA | 11.07M | 10.58M | 10.22M |
| Free Cash Flow | 5.66M | 4.59M | 4.29M |
| Rev Growth | -8.1% | +18.1% | +3.5% |
| Debt/Equity | 0.85 | 0.76 | 0.75 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |